Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Claudia Marchetti; I. Palaia; F. De Felice; A. Musella; C. Donfracesco; L. Vertechy; A. Romito; I. Piacenti; D. Musio; L. Muzii; V. Tombolini; P. Benedetti Panici

doi:10.1016/j.ctrv.2015.10.011

Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Claudia Marchetti
, I. Palaia
, F. De Felice
, A. Musella
, C. Donfracesco
, L. Vertechy
, A. Romito
, I. Piacenti
, D. Musio
, L. Muzii
, V. Tombolini
, P. Benedetti Panici

University of Rome La Sapienza

Research output: Contribution to journal › Article

Abstract

For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

Original language	English
Pages (from-to)	41-46
Number of pages	6
Journal	Cancer Treatment Reviews
Volume	42
DOIs	https://doi.org/10.1016/j.ctrv.2015.10.011
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Gynecologic
Ovarian cancer
Platinum resistant
Recurrence
Tyrosine-kinases inhibitors

Access to Document

10.1016/j.ctrv.2015.10.011

Cite this

@article{d7ebb6afea494c119c0c61ad16953abe,

title = "Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients",

abstract = "For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85\% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.",

keywords = "Gynecologic, Ovarian cancer, Platinum resistant, Recurrence, Tyrosine-kinases inhibitors, Gynecologic, Ovarian cancer, Platinum resistant, Recurrence, Tyrosine-kinases inhibitors",

author = "Claudia Marchetti and I. Palaia and \{De Felice\}, F. and A. Musella and C. Donfracesco and L. Vertechy and A. Romito and I. Piacenti and D. Musio and L. Muzii and V. Tombolini and \{Benedetti Panici\}, P.",

year = "2016",

doi = "10.1016/j.ctrv.2015.10.011",

language = "English",

volume = "42",

pages = "41--46",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

AU - Marchetti, Claudia

AU - Palaia, I.

AU - De Felice, F.

AU - Musella, A.

AU - Donfracesco, C.

AU - Vertechy, L.

AU - Romito, A.

AU - Piacenti, I.

AU - Musio, D.

AU - Muzii, L.

AU - Tombolini, V.

AU - Benedetti Panici, P.

PY - 2016

Y1 - 2016

N2 - For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

AB - For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

KW - Gynecologic

KW - Ovarian cancer

KW - Platinum resistant

KW - Recurrence

KW - Tyrosine-kinases inhibitors

KW - Gynecologic

KW - Ovarian cancer

KW - Platinum resistant

KW - Recurrence

KW - Tyrosine-kinases inhibitors

UR - http://hdl.handle.net/10807/205128

U2 - 10.1016/j.ctrv.2015.10.011

DO - 10.1016/j.ctrv.2015.10.011

M3 - Article

SN - 0305-7372

VL - 42

SP - 41

EP - 46

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -

Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this